The measurement of levels of amyloid-β (Aβ42), total-tau (t-tau), and phospho-tau181 (p-tau) in cerebrospinal fluid (CSF) can support the differential diagnosis of AD, and support the prediction of those individuals with mild cognitive impairment (MCI) potentially converting to AD in the future3–5. Here, MAPT is linked to Cognitive impairment.